The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 05, 2016
Filed:
Apr. 11, 2014
Applicant:
Wisconsin Alumni Research Foundation, Madison, WI (US);
Inventors:
Igor I. Slukvin, Madison, WI (US);
Kran Suknuntha, Madison, WI (US);
Assignee:
Wisconsin Alumni Research Foundation, Madison, WI (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/713 (2006.01); A61K 31/506 (2006.01); G01N 33/50 (2006.01); C12N 5/095 (2010.01); C12N 5/0789 (2010.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61K 31/496 (2006.01); A61K 31/5025 (2006.01); A61K 31/517 (2006.01); C12N 5/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 45/06 (2013.01); C12N 5/0647 (2013.01); C12N 5/0695 (2013.01); G01N 33/5011 (2013.01); G01N 33/5044 (2013.01); G01N 33/57426 (2013.01); C12N 2501/125 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/26 (2013.01); C12N 2502/1358 (2013.01); G01N 2333/9121 (2013.01); G01N 2500/10 (2013.01);
Abstract
Disclosed herein are compositions and methods to treat and reduce therapeutic resistance in chronic myelogenous leukemia. Also disclosed herein are methods to generate leukemia stem cell like cells (iLSCs) generated from CML patient-derived iPSCs, and methods for utilizing iLSCs in screens to identify modulators of CML drug resistance and gene targets that underlie CML drug resistance.